Last updated: May 27, 2026
Dovonex is calcipotriol (vitamin D analog) for psoriasis, marketed by Leo Pharma in multiple countries. Supply is typically executed through branded-drug contract manufacturers, with active pharmaceutical ingredient and packaging sourced through established pharma supply chains. However, a complete, patent- and label-accurate “suppliers list” (API manufacturers, finished-dose packers, and country-specific distributor/manufacturer of record) cannot be produced from the information provided.
If you need a supplier map for business use, Dovonex’s commercial reality is that manufacturers vary by market, and the “supplier” can mean one of three different entities: (1) marketing authorization holder (brand owner), (2) manufacturer of the finished drug product (or labeler/manufacturer of record), and (3) API starting material/active ingredient suppliers. Without a specified geography and product strength/formulation (cream vs ointment; and the exact national presentation), any supplier list risks being incomplete or wrong.
What companies supply Dovonex calcipotriol and who is the marketing authorization holder?
Answer: Leo Pharma is the brand owner and marketing authorization holder for Dovonex in most markets where it is authorized.
Who is the brand owner for Dovonex?
- Leo Pharma (global brand owner for Dovonex and related calcipotriol products).
What “supplier” typically means in Dovonex procurement
Procurement teams usually need one or more of:
- Finished dosage manufacturer (the entity on the pack as manufacturer of record)
- API manufacturer (calcipotriol substance supplier)
- Excipients and packaging suppliers (less visible in public datasets, more relevant for supply continuity)
Which manufacturers make Dovonex cream or ointment by country?
Answer: Finished-dose manufacturers differ by national approval and distribution chain; Leo Pharma can be the labeler while different contract manufacturers produce the cream/ointment in different countries.
How to map “manufacturer of record” correctly
A correct supplier map requires using the specific country label and strength because:
- Manufacturing site is tied to local marketing authorization
- Labeler and manufacturer of record differ from the brand owner
- Sterile is not relevant here (topical), but batch release sites still differ
What API suppliers provide calcipotriol for Dovonex?
Answer: Dovonex uses calcipotriol API supplied through specialty pharma ingredient supply chains; public identification of exact API suppliers is often non-trivial without country label manufacturing details and substance listings.
Why calcipotriol API supply lists are hard to confirm
- API supplier identity is frequently embedded in regulatory filings, rather than on consumer-facing packaging
- Multi-source supply is common; suppliers can rotate by batch and market
What excipients and packaging suppliers matter for Dovonex supply continuity?
Answer: For topical calcipotriol, continuity risk typically comes from:
- Emulsion/base excipients (for cream) and ointment base ingredients
- Primary packaging components (tubes, closures, cartons) and line clearance capacity
- Batch release capacity at finished-dose manufacturer sites
Practical risk hotspots for topical vitamin D analogs
- Specialty emulsion components and preservative systems (depending on the labeled formulation)
- Tube and closure supply lead times
- Finished-dose batch compression capacity during peak psoriasis season
How does Dovonex supplier structure affect pricing, availability, and backorders?
Answer: Availability is driven more by finished-dose contract manufacturing capacity and distribution than by brand-owner ownership of the label. API constraints can still bind, especially when suppliers consolidate for niche APIs like calcipotriol.
Business implications
- Contract manufacturer downtime or line qualification delays cause immediate supply gaps
- API lead time increases affect batch release schedules and warehouse cover
- Market-specific manufacturing makes “global backorder” patterns misaligned with brand-owner headcount
What competitive supplier landscape exists for calcipotriol topicals?
Answer: The calcipotriol market includes multiple branded and generic/follow-on presentations across countries. Supplier networks overlap at the contract-manufacturer and excipient/packager level.
Where substitution risk shows up
- In markets where calcipotriol creams/ointments are generic, packaging and manufacturing partners can overlap between competing products
- Supply chain leverage shifts when multiple SKUs are produced on shared lines
Key takeaways
- Leo Pharma is the brand owner and marketing authorization holder for Dovonex in most markets.
- The actual “supplier” to procurement depends on the definition: labeler (brand owner) vs manufacturer of record (finished-dose) vs API supplier.
- Without the specific country presentation (cream vs ointment, strength) and product listing details, a definitive supplier list cannot be produced without risking incorrect attribution.
FAQs
- Who is the manufacturer of record for Dovonex in the US versus the UK?
- What calcipotriol API suppliers support Dovonex supply chains?
- Which contract manufacturing sites produce Dovonex topical formulations?
- Do excipient and tube/closure suppliers change between Dovonex batches?
- How do contract-manufacturing constraints affect Dovonex availability during demand spikes?
References
- Leo Pharma. (n.d.). Dovonex product information (company materials).
